|
MechanismPDE5A inhibitors |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.United States |
First Approval Date27 Mar 1998 |
100 Clinical Results associated with Laboratorios Rubio SA /Bandol Brand/
0 Patents (Medical) associated with Laboratorios Rubio SA /Bandol Brand/
100 Deals associated with Laboratorios Rubio SA /Bandol Brand/
100 Translational Medicine associated with Laboratorios Rubio SA /Bandol Brand/